New funding and ad support aim to ease capital gaps for small wedding businesses
Updated
March 17, 2026 1:01 AM
Mannequins display white wedding dresses in a bridal shop window. PHOTO: ADOBE STOCK
The Knot Worldwide, a global wedding technology platform and vendor marketplace, has launched a new grant initiative aimed at small businesses in the wedding industry.
The company, which operates brands such as The Knot and WeddingWire, connects couples with wedding professionals and provides tools to help vendors grow. It says the new WeddingPro Grant Program is designed to address a persistent challenge in the sector: access to capital.
Under the program, up to US$500,000 will be distributed to U.S.-based wedding professionals who run small businesses. The support will come in the form of financial grants, advertising credits on WeddingPro and mentorship. Selected businesses will also receive access to education resources and community support through the company’s network.
The move comes at a time when many wedding businesses remain small and resource-constrained. According to the company’s State of the Vendor Report, more than half of wedding businesses employ fewer than ten people. Three in four professionals surveyed said adaptability is critical to long-term success, while flexible funding remains a barrier. The grant program is positioned as a response to that funding gap.
“Our mission at The Knot Worldwide is to help the nearly 900,000 small businesses on our global platforms get discovered through our centralized vendor marketplace as well as give them the tools and resources to grow their business,” said Raina Moskowitz, Chief Executive Officer, The Knot Worldwide. “We consistently hear from our wedding professionals that access to capital is a barrier to getting started in the industry. With our new WeddingPro Grant Program, we will provide access to both capital and critical support services such as mentorship and education that will enable small business owners to further grow and scale.”
The application window opens on February 23 and closes on March 27. Winners are expected to be notified by May 2026, subject to eligibility verification and compliance with the official rules.
The program is open to U.S. wedding professionals who operate small businesses, have been in business for at least six months, can demonstrate an active revenue stream and earn at least 50% of their revenue from weddings. Applicants must submit a short form and a video outlining their business and how they would use the grant funds over the next 12 to 24 months. They can choose whether they prefer a monetary grant or free advertising support on WeddingPro.
To execute the program, The Knot Worldwide has partnered with the Global Entrepreneurship Network, which works with entrepreneurs worldwide. The company says the initiative builds on earlier efforts to support vendors on its platform, which includes about 200,000 wedding professionals in the United States. Its impact will depend on how effectively the support reaches the businesses that need it most. The real measure will be whether it helps them achieve steady, sustainable growth.
Keep Reading
METiS TechBio’s blockbuster IPO signals rising investor interest in AI startups focused on how drugs are delivered inside the body
Updated
May 14, 2026 3:02 PM
HIV-1 virus particles, coloured red. PHOTO: UNSPLASH
Investors are beginning to place bigger bets on AI startups focused on drug delivery infrastructure rather than drug discovery alone. That shift was on display this week after METiS TechBio, a Hong Kong tech-bio startup focused on AI-powered drug delivery systems, debuted on the Hong Kong Stock Exchange.
The listing made METiS TechBio the world’s first publicly traded AI-powered drug delivery startup and the first AI-powered large-molecule biopharmaceutical startup listed in Hong Kong. The startup raised more than HKD 2.1 billion through its IPO, making it the largest healthcare listing in Hong Kong so far in 2026.
Investor demand was unusually strong. The Hong Kong public offering was oversubscribed by more than 6,900 times while the international tranche recorded 82 times oversubscription. More than 280 institutional investors participated in the international placing.
The strong demand reflects a wider shift in AI biotech. Over the past few years, much of the sector’s attention has focused on using AI to discover new drugs or molecules. METiS is taking a different approach. The startup focuses on how medicines are delivered inside the body after they are developed.
That challenge is becoming harder to ignore in biotech. Designing a therapy is only one part of the process. Delivering it precisely to specific organs, tissues or cells remains a major hurdle, especially for newer therapies involving RNA, proteins and large-molecule drugs.
METiS is trying to solve that problem through its proprietary NanoForge platform. The system uses AI to design and test nanodelivery systems that help medicines reach targeted areas inside the body more efficiently. The platform combines AI models, simulation systems and high-throughput screening tools to speed up formulation development and improve delivery precision.
The startup says it has already achieved targeted delivery across eight organs and tissue systems including the liver, lungs, heart, muscles and central nervous system.
One of its lead programs, MTS-004, became China’s first AI-enabled formulation drug to complete a Phase III clinical trial. The drug is being developed for pseudobulbar affect, a neurological condition that affects emotional expression. According to the startup, AI tools helped reduce preclinical formulation development time from up to two years to less than three months.
Investor interest in the IPO also came from some of the world’s largest asset managers and healthcare funds. BlackRock led the cornerstone investments with a USD 50 million subscription. Other participating investors included UBS Asset Management Singapore, Mirae Asset, ORIX Corporation, Deerfield, RTW, Hillhouse Capital and IDG Capital.
METiS is also building what it describes as a “platform collaboration + product partnership” business model. The startup currently works with more than 30 pharmaceutical and biotechnology partners globally, including large pharmaceutical companies and medical research institutions.
The company reported RMB 105 million in revenue in 2025, largely tied to upfront payments connected to its MTS-004 partnership agreements. It also said some platform collaboration contracts could reach milestone values of up to USD 109 million.
Chris Lai said: "The future of biomedicine will no longer be simply about 'taking medicine when one falls ill.' METiS TechBio's ambition is to harness AI to build nano-rockets that can navigate with precision through the inner space of the human body's 30 trillion cells, write the code of nucleic acids and proteins into cells, and reprogram diseased and aging cells into healthy cells. This was our founding aspiration, and it is the mission to which we will dedicate our lives. The IPO marks a new starting point for us to accelerate forward, and we will strive to live up to the support and trust we have received from all sectors."
The IPO also highlights how Hong Kong is increasingly positioning itself as a hub for next-generation biotech and AI healthcare startups. While investor excitement around AI drug discovery has cooled in parts of the market, startups focused on delivery systems and biotech infrastructure are beginning to attract stronger institutional backing.
For METiS, the challenge now will be turning that investor confidence into commercially viable therapies and long-term partnerships. But the listing suggests that AI-driven drug delivery is starting to emerge as a category investors are willing to treat as core biotech infrastructure rather than a niche research experiment.